IRIS
STEFANI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 58.083
AS - Asia 15.153
EU - Europa 5.026
SA - Sud America 1.125
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 10
Totale 79.505
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 57.901
SG - Singapore 12.542
IE - Irlanda 985
CN - Cina 970
BR - Brasile 961
UA - Ucraina 833
HK - Hong Kong 806
IT - Italia 694
DE - Germania 675
RU - Federazione Russa 378
FR - Francia 348
GB - Regno Unito 300
VN - Vietnam 277
SE - Svezia 239
PL - Polonia 162
FI - Finlandia 155
KR - Corea 145
CA - Canada 97
NL - Olanda 77
IN - India 73
AR - Argentina 65
ID - Indonesia 58
JP - Giappone 55
MX - Messico 54
AT - Austria 46
BD - Bangladesh 45
ZA - Sudafrica 33
ES - Italia 29
IQ - Iraq 29
EC - Ecuador 25
BE - Belgio 24
TR - Turchia 24
EU - Europa 23
CO - Colombia 20
UZ - Uzbekistan 20
PY - Paraguay 15
VE - Venezuela 15
CZ - Repubblica Ceca 14
KG - Kirghizistan 14
MA - Marocco 14
CL - Cile 13
PK - Pakistan 13
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 9
EG - Egitto 9
AU - Australia 8
CH - Svizzera 8
IL - Israele 8
KE - Kenya 8
LT - Lituania 8
RO - Romania 8
IR - Iran 7
PE - Perù 7
AL - Albania 6
BG - Bulgaria 6
JM - Giamaica 6
MY - Malesia 6
GE - Georgia 5
GR - Grecia 5
HN - Honduras 5
NP - Nepal 5
PH - Filippine 5
PT - Portogallo 5
TN - Tunisia 5
AZ - Azerbaigian 4
LB - Libano 4
NG - Nigeria 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
BO - Bolivia 3
DK - Danimarca 3
DM - Dominica 3
DO - Repubblica Dominicana 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
BB - Barbados 2
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
CD - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
GD - Grenada 1
GT - Guatemala 1
HU - Ungheria 1
Totale 79.494
Salva come PNG Salva come JPEG
Città #
Wilmington 15.727
Houston 15.007
Woodbridge 13.898
Fairfield 2.237
Singapore 1.459
Ashburn 1.129
Ann Arbor 1.106
Seattle 869
Hong Kong 804
Cambridge 761
Jacksonville 756
Chandler 727
Dublin 655
Beijing 518
Medford 502
Dearborn 413
Santa Clara 313
Rome 248
Lawrence 233
The Dalles 216
Los Angeles 194
New York 184
Buffalo 127
San Diego 116
Kraków 110
Menlo Park 109
Munich 102
São Paulo 82
Council Bluffs 79
Ho Chi Minh City 77
Hanoi 74
Moscow 73
London 70
Dallas 65
Redondo Beach 57
Milan 53
Chicago 50
Mülheim 49
Brooklyn 46
Nuremberg 44
Norwalk 43
Warsaw 42
Phoenix 41
Redwood City 39
Amsterdam 38
Jakarta 37
Zhengzhou 37
Tokyo 36
Stockholm 34
Montreal 32
Toronto 31
Hefei 30
Rio de Janeiro 30
Shanghai 30
Boston 29
Atlanta 28
Chennai 28
Seoul 28
Verona 28
Denver 27
Palo Alto 27
Durham 26
Johannesburg 26
Orem 25
Belo Horizonte 23
Boardman 23
Mexico City 23
Brussels 22
Kunming 22
San Jose 22
Falls Church 21
Nanjing 21
Salt Lake City 21
Elk Grove Village 20
Manchester 20
Mountain View 20
St Louis 20
Helsinki 19
University Park 19
Guangzhou 16
Salvador 16
Dhaka 15
Poplar 15
Brasília 14
Guarulhos 14
Florence 13
San Francisco 13
Turku 13
Vienna 13
Curitiba 12
Haiphong 12
Kilburn 12
Mcallen 12
Porto Alegre 12
Saint Petersburg 12
Tashkent 12
Ankara 11
Biên Hòa 11
Chengdu 11
Creede 11
Totale 60.697
Salva come PNG Salva come JPEG
Nome #
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 603
The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway. 596
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 592
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 582
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 578
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 577
Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following reserpine treatment: focus on kappa response. 576
Therapy for dyskinesias in Parkinson’s disease patients 574
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 572
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 572
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 571
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 556
Posterior cortical atrophy with unilateral occipito-temporal degeneration 552
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 548
Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects 535
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 535
Re: Stereotactic microdialysis of the basal ganglia in Parkinson's disease 534
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 529
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 522
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 522
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 512
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 507
Neuroacanthocytosis associated with a defect of the 4.1R membrane protein 506
Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease 489
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 489
Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease 484
Clinical and genetic study of a large SPG4 Italian family 483
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 480
Do CSF levels of t-Tau, p-Tau and beta(1-42) amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A I-123-FP-CIT study in the early stages of the disease 479
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 473
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 470
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. 469
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 467
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 465
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission 462
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 461
Selective vulnerability of pallidal neurons in the early phases of manganese intoxication 459
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 456
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 456
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 456
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 455
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 450
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration 449
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 448
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 444
Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: a challenge for the 6-OHDA model? 443
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 442
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents 442
Acute nigro-striatal blockade alters cortico-striatal encoding: An in vivo electrophysiological study 441
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 439
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 437
A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices 433
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 431
Neurotensin effects on N-type calcium currents among rat pallidal neurons: an electrophysiological and immunohistochemical study. 431
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 430
Distinct roles of cortical and pallidal β and γ frequencies in hemiparkinsonian and dyskinetic rats 430
Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. 425
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 424
Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons 422
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 421
Subthalamic stimulation and levodopa modulate cortical reactivity in Parkinson's patients 421
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 420
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 420
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 416
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 415
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 415
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 415
Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives 414
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 413
Vulnerability of medium spiny striatal neurons to glutamate: role of Na+/K+ ATPase 410
Outward potassium currents activated by depolarization in rat globus pallidus 410
Association analysis between Alzheimer's disease and the Nicastrin gene polymorphisms 410
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 409
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 407
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 407
Thalamic ¹²³I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression 405
Alexithymia is a non-motor symptom of Parkinson disease 404
In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. 403
Pramipexole in comparison to l-dopa: a neuropsychological study 403
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients 394
The modulation of calcium currents by the activation of mGluRs. Functional implications 393
Catecholamine-based treatment in AD patients: expectations and delusions 393
D2-mediated modulation of N-type calcium currents in rat globus pallidus neurons following dopamine denervation 392
The modulation of dopamine receptors in rat striatum 392
Theta Burst Stimulation Modulates Cerebellar-Cortical Connectivity in Patients with Progressive Supranuclear Palsy 390
CSF biomarker variability in the Alzheimer's Association quality control program 390
Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on "CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al 390
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 389
Basic research in substantia nigra and ventral tegmental area: clinical implications 389
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 388
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 386
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 380
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 380
Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients 378
Association study of the 5-hydroxytryptamine(6) receptor gene in Alzheimer's disease 377
Adherence to anti-Parkinson drug therapy in the "rEASON" sample of Italian patients with Parkinson's disease: The linguistic validation of the Italian version of the "morisky Medical Adherence scale-8 items" 377
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 376
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers 376
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 375
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug 374
Totale 45.382
Salva come PNG Salva come JPEG
Categoria #
all - tutte 184.924
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 184.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.501 0 0 0 0 0 1.203 1.227 1.001 252 209 507 102
2021/20222.850 59 351 139 125 89 153 599 146 135 143 234 677
2022/20232.216 275 161 80 219 170 606 247 117 170 6 120 45
2023/2024874 91 34 66 19 87 146 36 144 22 57 14 158
2024/202515.481 174 1.280 598 337 113 477 470 351 650 525 6.031 4.475
2025/20264.475 836 385 1.191 927 893 243 0 0 0 0 0 0
Totale 80.516